Clinical Trials Logo

T-cell Non-Hodgkin Lymphoma clinical trials

View clinical trials related to T-cell Non-Hodgkin Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06420089 Not yet recruiting - Clinical trials for T Cell Non-Hodgkin Lymphoma

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

VIPER101
Start date: June 30, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.